Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | BCR | P11274 | 2/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036777 | 0.86 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1HPGDCA12CA1 | |
| SCHEMBL2536884 | 0.86 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1HPGDCA12CA1 | |
| SCHEMBL12509138 | 0.86 | PARP1 (0.59) | L3MBTL1ALDH1A1HPGDHSD11B1MEN1 | |
| SCHEMBL7251916 | 0.86 | MEN1 (0.77) | L3MBTL1ALDH1A1HPGDSIGMAR1ABL1 | |
| SCHEMBL2534098 | 0.85 | L3MBTL1 (0.74) | L3MBTL1ALDH1A1HPGDCA12CA1 | |
| SCHEMBL16026516 | 0.84 | ALDH1A1 (0.61) | ALDH1A1SIGMAR1 | |
| SCHEMBL8358286 | 0.84 | SIGMAR1 (0.76) | L3MBTL1ALDH1A1HPGDSIGMAR1 | |
| SCHEMBL13504020 | 0.84 | ALDH1A1 (0.74) | L3MBTL1ALDH1A1HPGDCA12CA1 | |
| SCHEMBL26296156 | 0.84 | ALDH1A1 (0.74) | L3MBTL1ALDH1A1HPGDCA12CA1 | |
| Hydrochloric Acid SCHEMBL9621122 | 0.83 | ALDH1A1 (0.60) | ALDH1A1HPGDSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11479564-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | VALO HEALTH, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| CN-104262244-B | A kind of 5-phenylpyridine-2-amine Bcr-Abl inhibitor and its preparation method and application | Xi''an Jiao Tong University (CN) | 2017-01-04 | — | — | CN | disclosed |
| CN-104262244-A | 5-phenylpyridine-2-amine Bcr-Abl inhibitors as well as preparation method and application thereof | UNIV XI AN JIAOTONG | 2015-01-07 | — | — | CN | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-0250361-B1 | Disubstituted piperazines | CIBA GEIGY AG (CH) | 1993-12-08 | — | — | EP | disclosed |
| US-4804661-A | ANALGESICS | CIBA-GEIGY CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
| EP-0250361-A2 | Disubstituted piperazines | CIBA-GEIGY AG (CH) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | L3MBTL1 4177/4885ALDH1A1 265/4885HPGD 105/4885 |
| US-11479564-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | NAMPT, NAPRT, NNMT | L3MBTL1 4177/4885ALDH1A1 265/4885HPGD 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.